Rexahn’s RX-3117 gets FDA orphan drug status for pancreatic cancer treatment
Currently, the company is enrolling cancer patients in a Phase Ib clinical trial and expects to complete the trial in the first quarter of 2015. In preclinical trials,
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.
In addition to this recently allowed application, the patent family includes applications pending in other major markets including Australia, Canada, China, Europe and Japan. The exclusively licensed technology